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The recent approval of a therapeutic for a circadian disorder has increased interest
in developing additional medicines for disorders characterized by circadian disruption.
However, previous experience demonstrates that drug development for central nervous
system (CNS) disorders has a high failure rate. Personalized medicine, or the approach to
identifying the right treatment for the right patient, has recently become the standard for
drug development in the oncology field. In addition to utilizing Companion Diagnostics
(CDx) that identify specific genetic biomarkers to prescribe certain targeted therapies,
patient profiling is regularly used to enrich for a responsive patient population during
clinical trials, resulting in fewer patients required for statistical significance and a higher
rate of success for demonstrating efficacy and hence receiving approval for the drug.
This personalized medicine approach may be one mechanism that could reduce the high
clinical trial failure rate in the development of CNS drugs. This review will discuss current
circadian trials, the history of personalized medicine in oncology, lessons learned from a
recently approved circadian therapeutic, and how personalized medicine can be tailored
for use in future clinical trials for circadian disorders to ultimately lead to the approval of
more therapeutics for patients suffering from circadian abnormalities.
Keywords: personalized medicine, circadian disorders, circadian therapeutics, patient enrollment, companion
diagnostics, targeted therapeutics
Introduction
The approval of HETLIOZ R© (tasimelteon) for Non-24 disorder has reignited an interest in
developing therapeutics for circadian abnormalities. However, as the history of tasimelteon
demonstrates, the path to approval of a drug for a circadian dysfunction is not an easy one. One
component of the challenge is the ability to match the therapeutic approach to the patient most
likely to benefit from the intervention, a model often called personalizedmedicine. Patient selection
or optimization of therapy is guided in some indications by genetic or biochemical markers which
point to the underlying molecular mechanisms causing disease. In central nervous system (CNS)
disorders, genetic markers have been difficult to pinpoint, possibly because the clinical symptoms
actually represent multiple diseases with different molecular drivers. However, treating circadian
dysfunction has an advantage over other CNS disorders, in that the phenotype of the disorder is
relatively easy to measure, is highly translatable from animal models to humans, and modulation of
the phenotype can be quantified, providing an accessible proof of mechanism biomarker. Here
we review the recent history of clinical trials for circadian disorders; conduct a comparison to
oncology, where personalized approaches have greatly improved success for therapeutics; and
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discuss the challenges that remain in circadian medicine to
incorporate personalized approaches to improve the approval
rate of medicines for circadian disorders.
Background
Circadian clocks regulate a plethora of biological processes.
Cellular processes such as gene expression and physiological
processes such as body temperature, hormone and
neurotransmitter release, as well as behaviors including
activity, sleep, learning and memory are under circadian control.
Recent advances in understanding the molecular components
of the clock, together with global transcriptome approaches,
provided insight into the vast extent of the genetic landscape
regulated by the clock, helping to explain at the molecular
level how such a variety of physiological systems are circadian-
regulated. The cycling clock proteins (BMAL1, CLOCK, PER-1
and -2, CRY-1 and -2) directly bind to gene regulatory elements
and regulate thousands of transcripts in multiple tissues in a
temporally coordinated manner (Koike et al., 2012). Recent
genome-wide studies have shown that an astonishing 43%
of genes are transcribed with a rhythmic pattern in a largely
tissue-specific manner (Zhang et al., 2014). Finally, epigenetic
mechanisms of gene regulation are also clock-controlled; a
large number of non-coding RNAs are rhythmically expressed.
Among these cycling mRNAs, only about half are regulated by
de novo transcription; post-transcriptional regulation is also
modulated by circadian input.
This recent understanding of the enormous impact of the
clock on the human organism and the elucidation of the
molecular components of the clock provide the pharmaceutical
industry with potential targets that should prove fruitful for the
discovery and development of new therapeutics. As of late 2014,
there were 34 open clinical trials listed at https://clinicaltrials.gov/
that included the keyword “circadian.” The purpose of several of
these trials is to phenotype circadian rhythms in specific patient
populations, for example the NIAAA study on the circadian
dopamine rhythm in cocaine addicts (Table 1, NCT02233829)
and the UCSF study on sleep disruption and delirium
(Table 1, NCT01280097). Other trials are studying behavioral
interventions to alter circadian rhythms, for example a study at
Rhode Island Hospital using chronobiological interventions to
treat post-partum depression (Table 1, NCT02053649). Several
studies are testing the efficacy of melatonin in various patient
populations or the efficacy of the approved drugs Modafinil,
Circadin, and tasimelteon for new indications. Disappointingly,
no trials listed novel agents for primary circadian disorders,
such as advanced- or delayed-phase syndromes, or for circadian
disorders secondary to other diseases, such as sundowning in
Alzheimer’s disease patients, despite the prevalence of these
disorders. Sundowning, for instance, has been reported in 2.4–
25% patients diagnosed with Alzheimer’s disease (AD). Thus, it
appears that drug development for circadian dysfunction remains
an under-invested area, although the growing understanding
of the profound impact of circadian patterns of expression
of the majority of human genes in both healthy and sick
individuals may stimulate research into potential therapies for
circadian disorders. Several major pharmaceutical companies
appear to be invested in programs aimed at molecular targets
associated with circadian biology. These including programs
on inhibitors of casein kinase 1 (CK1, Pfizer, and Amgen)
(Sprouse et al., 2010; Long et al., 2012), which is also a target
of interest in oncology. In addition, the growing appreciation
of the intimate role of clock proteins in metabolism is reflected
in research programs in major pharmaceutical and several
biotech companies, including projects examining Cry1 [(Griebel
et al., 2014); Reset Therapeutics (http://resettherapeutics.com/
programs/)] and REV-ERB (Kojetin and Burris, 2014).
This review will discuss why trials for circadian disorders risk
a high failure rate, what has been learned from the more recent
success with the approval of tasimelteon (HETLIOZ R©), and what
can be done in the future to reduce the risk of clinical trial failures
and improve the chances of delivering medications to patients
suffering from circadian disorders.
Human Circadian Clocks
Humans, in common with most (if not all) living organisms,
have biological clocks that organize the timing of physiological
events and keep them synchronized with the external 24-h
day. This coordination with the 24-h day led to the term
“circadian.” The master circadian clock in mammals resides in
the suprachiasmatic nucleus (SCN) of the hypothalamus (Meijer
and Rietveld, 1989). Rhythms generated by the SCN clock are
autonomous (i.e., they do not depend upon environmental cues),
but under normal conditions and in healthy individuals the
timing of the internal oscillator is synchronized with the external
24-h day by environmental stimuli, principally light. In addition
to the master SCN pacemaker, other tissues and organs also
possess cellular clocks that are synchronized by signals from the
SCN. These peripheral circadian clocks regulate the timing of
many metabolic and cellular processes that are specific to the
function of the particular cell type and tissue (Mohawk et al.,
2012).
The human clock cycles with a period (tau) of nearly,
but not exactly, 24 h. When an individual is placed into
an environment removed from any time cues (free-running
conditions), the inherent period of the internal clock is revealed;
tau has been measured at 24 h 11 ± 16min (Czeisler et al.,
1999). Environmental light normally keeps the internal clock
synchronized or entrained to the external day-night cycle. This
synchronization is accomplished by an adjustment in the phase of
the oscillation, or phase shift, whenever a disparity exists between
the internal “time of day” and external lighting conditions. For
example, if the internal clock is slow, or delayed, morning light
occurring before the internal clock “anticipates” it will advance
the phase of the clock; whereas, in a clock running fast, light in
the evening will delay the phase of the clock. Light occurring
coincident with the internal “daytime” will not shift the clock.
The differential effects of light at different times relative to the
internal phase can be measured and plotted as a phase-response
curve (PRC). The PRCs of humans and other diurnal mammals
compared to nocturnal mammals are generally similar—light
in the early subjective night lead to a phase delay, while light
in the late subjective night lead to an advance, keeping the
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TABLE 1 | Open drug intervention clinical trials in clinicaltrials.gov that include “circadian,” “clock,” or “chronobiology” as a keyword.
Sponsor/Collaborators Interventions Conditions Phase NCT Number
University of Chicago Drug: exenatide and Placebo Type 2 diabetes; sleep disordered breathing NP NCT01136798
Xinhua Hospital; Shanghai Jiao Tong
University School of Medicine
Drug: etomidate; midazolam; propofol Congenital hydronephrosis; congenital
choledochal cyst; fracture
Phase 4 NCT02013986
Universitätsklinikum Hamburg-Eppendorf Drug: Melatonin 2mg and Placebo Healthy night shift workers, sleep disorders Phase 3 NCT02108353
Mount Sinai School of Medicine; National
Institute of Mental Health (NIMH)
Drug: Modafinil and Placebo Bipolar disorder Phase 4 NCT01965925
Stanford University; Patient Centered
Outcome Research Institute
Other: CONV care for the diagnosis
and treatment of sleep disorders
Other: PCCM for the diagnosis and
treatment of sleep disorders
Obstructive sleep apnea of adult; insomnia;
circadian rhythm sleep disorder,
unspecified type; restless legs syndrome;
narcolepsy and hypersomnia
NP NCT02037438
National Institute on Alcohol Abuse and
Alcoholism (NIAAA); National Institutes of
Health Clinical Center (CC)
Drug: brain dopamine reactivity
methylphenidate; brain dopamine
receptor C-11 raclopride
Cocaine abuse Phase 0 NCT02233829
Rhode Island Hospital; The Depressive
and Bipolar Disorder Alternative
Treatment Foundation
Behavioral: triple chronotherapy;
usual care
Depression; major depressive disorder;
post-partum depression
NP NCT02053649
Hopital Foch Drug: propofol; remifentanil Anesthesia, general Phase 3 NCT00896714
University of California, San Francisco;
Masimo Labs
NP Delirium; sleep disorders, circadian rhythm NP NCT01280097
National Human Genome Research
Institute (NHGRI); National Institutes of
Health Clinical Center (CC)
Drug: dTR Melatonin (NIH CC PDS);
melatonin CR
Device: phototherapy (bright light)
Developmental delay disorders;
chromosome deletion; mental retardation;
sleep disorders, circadian rhythm;
self-injurious behavior
Phase 1 NCT00506259
Oregon Health and Science University Drug: melatonin
Behavioral: regular sleep schedule;
light
Insomnia; blindness; daytime sleepiness NP NCT00911053
Hospital de Clinicas de Porto Alegre Drug: melatonin and Placebo;
amitriptyline and Placebo; melatonin
and amitriptylin
Fibromyalgia Phase 2
Phase 3
NCT02041455
Paracelsus Medical University;
Technische Universität München
Drug: testosterone supplementation Circadian; exercise; testosterone NP NCT02134470
Sogo Rinsho Médéfi Co., Ltd.; Takeda Drug: azilsartan; amlodipine Hypertension NP NCT01762501
Ann & Robert H Lurie Children’s Hospital
of Chicago; Children’s Research Institute
Drug: prednisone and Placebo Duchenne Muscular Dystrophy (DMD) Phase 2 NCT02036463
Brigham and Women’s Hospital Biological: melatonin and Placebo Delayed sleep phase disorder; jet-lag;
shift-work disorder
NP NCT00950885
Oregon Health and Science University;
Eunice Kennedy Shriver National Institute
of Child Health and Human Development
(NICHD)
Dietary supplement: melatonin
Biological: melatonin
Blindness NP NCT00691444
Prince of Songkla University Device: selective laser trabeculoplasty
Drug: travoprost
Intraocular pressure Phase 4 NCT02105311
Neurim Pharmaceuticals Ltd. Drug: circadin 2/5/10mg and
Placebo
Sleep disorders Phase 3 NCT01906866
(Continued)
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TABLE 1 | Continued
Sponsor/Collaborators Interventions Conditions Phase NCT Number
Hospices Civils de Lyon Drug: melatonin and Placebo Sleep disorders Phase 2 NCT01993251
University of Vigo Drug: aspirin Type 2 diabetes Phase 4 NCT00725127
University of Bergen Drug: paracetamol and
buprenorphine; paracetamol and
Placebo; buprenorphine and Placebo
Depression; pain; dementia Phase 4 NCT02267057
University of Pittsburgh; National Heart,
Lung, and Blood Institute (NHLBI)
Behavioral: modified ME intervention;
education only
Sleep apnea, obstructive Phase 1 NCT01377584
Herlev Hospital Drug: melatonin,
N-acetyl-5-methoxytryptamine;
isotonic saline, natrium chloride
Acute myocardial infarction;
ischemia-reperfusion injury
Phase 2 NCT01172171
Vanda Pharmaceuticals Drug: tasimelteon Smith-Magenis syndrome; circadian Phase 2 NCT02231008
University of British Columbia Drug: melatonin and Placebo Delirium Phase 4 NCT02282241
University of Michigan; University of
Pennsylvania; Washington University
Early Recognition Center
Drug: ISOFLURANE- experimental
arm
Other: control group: cognitive testing
Post-operative cognitive dysfunction NP NCT01911195
Haukeland University Hospital Drug: Solu-Cortef; Cortef Addison disease Phase 1
Phase 2
NCT02096510
Charite University; Technische Universität
München; University of
Erlangen-Nürnberg Medical School;
Praxis für Neurologie und Psychiatrie am
Prinzregentenplatz, München; Technische
Universität Berlin
Behavioral: patient centered
structured support program
Mini-stroke NP NCT01586702
Teva Pharmaceutical Industries; United
BioSource Corporation
Drug: modafinil; armodafinil Narcolepsy; obstructive sleep apnea; shift
work sleep disorder
NP NCT01792583
Vanda Pharmaceuticals Drug: tasimelteon Non-24-H sleep-wake disorder Phase 3 NCT01429116
Vanda Pharmaceuticals Drug: tasimelteon Non 24 H sleep wake disorder Phase 3 NCT01218789
Aretaieion University Hospital; Baxter
Healthcare Corporation
Procedure: maintenance with
desflurane
Procedure: maintenance with
propofol
Anesthesia; surgery; sleep disorders NP NCT02061514
Endo Pharmaceuticals Drug: morphine Sulfate 30 mg;
Oxycodone 20 mg; Morphine 45 mg;
Oxycodone 30 mg; Morphine sulfate
15 mg; Oxycodone 10 mg; morphine
Sulfate 30 mg; Oxycodone 15mg
Chronic around the clock opioid users Phase 2 NCT01871285
Mundipharma Research GmbH & Co KG Drug: Oxycodone/Naloxone
prolonged release (OXN PR) tablets;
oxycodone prolonged release
(OxyPR) tablets
Pain|Constipation Phase 3 NCT01438567
Brigham and Women’s Hospital|National
Center for Complementary and
Integrative Health (NCCIH)
Drug: vitamin B12 Sleep disorders, circadian rhythm NCT00120484
Endo Pharmaceuticals|BioDelivery
Sciences International
Drug: EN3409 Low back pain|Osteoarthritis|Neuropathic
pain
Phase 3 NCT01755546
(Continued)
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TABLE 1 | Continued
Sponsor/Collaborators Interventions Conditions Phase NCT Number
Mundipharma Research GmbH & Co KG Drug: Oxycodone; Naloxone Malignant pain|Non-malignant pain Phase
2|Phase 3
NCT02321397
Purdue Pharma LP Drug: Oxycodone/Naloxone
controlled-release; Placebo
Low back pain Phase 3 NCT01358526
Janssen Pharmaceutical K.K. Drug: tapentadol ER; morphine SR Neoplasms Phase 3 NCT01309386
Purdue Pharma LP Drug: Oxycodone/Naloxone
controlled-release; Oxycodone HCl
controlled-release; Placebo
Low back pain Phase 3 NCT01427270
Purdue Pharma LP Drug: oxycodone/naloxone
controlled-release; oxycodone HCl
controlled-release; Placebo
Low back pain Phase 3 NCT01427283
Oregon Health and Science
University|Forest Laboratories
Drug: Placebo/escitalopram Depression NCT01214044
Technische Universität
München|Cephalon
Drug: modafinil (Vigil); Placebo Depression Phase 2 NCT00670813
University of Copenhagen|
Rigshospitalet, Denmark
Drug: erythropoietin (Epoetin-beta,
NeoRecormon); erythropoietin
(Epoetin-beta, NeoRecormon);
Placebo
Renal effects Phase 1 NCT01584921
Norwegian University of Science and
Technology|St. Olavs
Hospital|Fondazione IRCCS Istituto
Nazionale dei Tumori, Milano|L’Hospitalet
de Llobregat|University Hospital,
Bonn|Cantonal Hospital of St.
Gallen|Maastricht University Medical
Center|Flinders University
Drug: intranasal fentanyl spray; slow
release morphine
Cancer|Pain Phase 3 NCT01906073
Endo Pharmaceuticals Drug: oxymorphone IR Chronic pain Phase 3 NCT01206907
Mundipharma Research GmbH & Co KG Drug: laxative Opioid induced constipation Phase 4 NCT01957046
Instituto Nacional de Ciencias Medicas y
Nutricion Salvador Zubiran
Drug: haloperidol; Placebo;
non-pharmacologic measures
Hypoactive delirium Phase 3 NCT02345902
University of Oklahoma Drug: memory XL; Placebo Mild cognitive impairment Phase 2 NCT00903695
University of Illinois at
Chicago|Genentech, Inc.
Drug: ranibizumab (lucentis) Glaucoma|New onset
Glaucoma|Neovascular Glaucoma|New
onset neovascular glaucoma
Phase
1|Phase 2
NCT00727038
Universitätsklinikum Hamburg-Eppendorf Drug: melatonin 2 mg; Placebo Healthy night shift workers, sleep disorders Phase 3 NCT02108353
Eunice Kennedy Shriver National Institute
of Child Health and Human Development
(NICHD)|National Institutes of Health
Clinical Center (CC)
Drug: hydrocortisone; Placebo;
hydrocortisone and melatonin;
melatonin
Jet lag syndrome Phase 2 NCT00097474
University of California, San
Diego|California Breast Cancer Research
Program
Device: light box (litebook) Breast cancer NCT00478257
St. Olavs Hospital Drug: fentanyl Chronic pain|Cancer Phase
1|Phase 2
NCT01248611
(Continued)
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TABLE 1 | Continued
Sponsor/Collaborators Interventions Conditions Phase NCT Number
National Heart, Lung, and Blood Institute
(NHLBI)
Drug: melatonin; methylxanthine
Device: light therapy
Sleep disorders, circadian rhythm NCT00387179
Takeda Drug: ramelteon; Placebo Circadian dysregulation Phase 4 NCT00492011
AstraZeneca Drug: AZD1386; Placebo Pain|Esophageal sensitivity Phase 1 NCT00711048
Delray Medical Center Drug: IV Ibuprofen Pain Phase 4 NCT02152163
Attikon Hospital Drug: sugammadex;
neostigmine/atropine
Post-operative cognitive dysfunction NCT02419352
Mundipharma Research GmbH & Co KG Drug: OXN PR followed by OxyPR
tablets; OxyPR followed by OXN PR
tablets
Severe chronic pain Phase 2 NCT01915147
Greater Houston Retina Research Drug: ranibizumab (lucentis) Ischemic central retinal vein occlusion Phase 1 NCT00406471
Pfizer Drug: donepezil Dementia, vascular|Dementia, mixed Phase 3 NCT00174382
Pfizer Drug: morphine sulfate extended
release capsules
Pain Phase 4 NCT00640042
Meander Medical Center|Dutch Kidney
Foundation
Drug: melatonin tablet 3mg once
daily; Placebo comparator
Sleep Problems|Haemodialysis Phase 3 NCT00388661
Meander Medical Center|Dutch Kidney
Foundation
Drug: melatonin Hemodialysis|Peritoneal dialysis|Sleep
problems
Phase 3 NCT00404456
Ever Neuro Pharma GmbH|acromion
GmbH|Geny Research Corp.
Drug: cerebrolysin; 0.9% saline
solution
Vascular dementia Phase 4 NCT00947531
Neovii Biotech Drug: catumaxomab; prednisolone Cancer|Neoplasms|Carcinoma|Malignant
ascites
Phase 3 NCT00822809
Singapore General
Hospital|Novartis|National Neuroscience
Institute
Drug: exelon (rivastigmine); placebo Cognitive impairment Phase 4 NCT00669344
University of Toledo Health Science
Campus
Drug: continuous release dopamine
agonists
Parkinson disease Phase 3 NCT00465452
Novartis Drug: rivastigmine capsule;
rivastigmine transdermal patch
Parkinson’s disease dementia Phase 3 NCT00623103
University of Rochester|Forest
Laboratories
Drug: namenda Delirium|Post-operative states Phase 4 NCT00303433
INSYS Therapeutics Inc Drug: fentanyl sublingual spray Cancer|Pain Phase 3 NCT00538863
Endo Pharmaceuticals|BioDelivery
Sciences International
Drug: EN3409; Placebo Low back pain Phase 3 NCT01633944
Endo Pharmaceuticals|BioDelivery
Sciences International
Drug: EN3409 Low back pain Phase 3 NCT01675167
Memorial Sloan Kettering Cancer Center Drug: d-Methadone; Placebo Pain|Bladder Cancer|Breast Cancer|CNS
Cancer|Colon Cancer|Esophageal
Cancer|Pancreatic Cancer|Prostate
Cancer|Uterine Cancer|Head and neck
Cancer|Eye Cancer|Otorhinolaryngologic
neoplasms
Phase
1|Phase 2
NCT00588640
(Continued)
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TABLE 1 | Continued
Sponsor/Collaborators Interventions Conditions Phase NCT Number
Neurim Pharmaceuticals Ltd. Drug: melatonin (circadin); Placebo Non-24 H sleep-wake disorder|Blindness Phase 2 NCT00972075
National Eye Institute (NEI) Drug: melatonin Blindness NCT00686907
Collegium Pharmaceutical, Inc. Drug: oxycodone DETERx; Placebo Chronic low back pain Phase 3 NCT01685684
Cephalon|Teva Pharmaceutical Industries Drug: ACTIQ (Oral Transmucosal
Fentanyl Citrate [OTFC])
Pain|Cancer|Sickle cell Anemia|Severe
burns
Phase 2 NCT00236093
Shaare Zedek Medical Center Drug: extended-release tramadol;
paracetamol
Post-operative pain NCT01024348
Cephalon|Teva Pharmaceutical Industries Drug: ACTIQ Cancer|Breakthrough pain Phase 2 NCT00236041
Accera, Inc. Drug: AC-1204; Placebo Alzheimer’s disease Phase
2|Phase 3
NCT01741194
Mundipharma Pharmaceuticals B.V. Drug: oxycodone hydrochloride and
naloxone hydrochloride combination,
prolonged release
Pain Phase 3 NCT01167127
Melissa Voigt Hansen|University of
Copenhagen|Rigshospitalet,
Denmark|Pharma Nord|Herlev Hospital
Drug: melatonin
(N-acetyl-5-methoxytryptamine);
Placebo
Breast cancer|Depression Phase
2|Phase 3
NCT01355523
Mundipharma Pharmaceuticals B.V. Drug: oxycodone and naloxone Pain Phase 3 NCT01167699
James Graham Brown Cancer
Center|University of Louisville
Drug: Fentanyl Citrate Nasal Spray
(FCNS)
Pain Phase 4 NCT01839552
Kaplan Medical Center Drug: oxycodone 10mg Elective laproscopic bilateral inguinal
Hernia|Elective laproscopic
cholecystectomy
Phase 4 NCT00480142
Brigham and Women’s Hospital|Takeda Drug: ramelteon; Placebo Healthy NCT00595075
Loma Linda University Drug: morphine PCA started at the
end of surgery, 1 Percocet 1/325mg
every 4 h; may receive a second
Percocet if needed. For the 30ml
ropivacaine the intervention would be
the subject can request extra pain
medication which would be Percocet
and/or morphine PCA
Post-op pain NCT01939379
Vanda Pharmaceuticals Drug: tasimelteon 20mg capsule;
tasimelteon 2mg I.V.
Non-24-H-sleep-wake disorder Phase 4 NCT02130999
Oregon Health and Science University Drug: melatonin Insomnia|Blindness|Daytime sleepiness NCT00911053
Erasmus Medical Center|ZonMw: The
Netherlands Organization for Health
Research and Development
Drug: enalapril/hydrochlorothiazide;
Placebo
Essential hypertension Phase 4 NCT02214498
National Institute on Alcohol Abuse and
Alcoholism (NIAAA)|National Institutes of
Health Clinical Center (CC)
Drug: brain dopamine reactivity; brain
dopamine receptor
Cocaine abuse Phase 0 NCT02233829
Boehringer Ingelheim Drug: telmisartan; ramipril Hypertension Phase 4 NCT00274612
Ottawa Heart Institute Research
Corporation|Schering-Plow|Medtronic
Drug: eptifibatide facilitated PCI Myocardial infarction Phase 3 NCT00251823
(Continued)
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TABLE 1 | Continued
Sponsor/Collaborators Interventions Conditions Phase NCT Number
Boehringer Ingelheim Drug: telmisartan combined with
hydrochlorothiazide (80/12.5 mg);
valsartan combined with
hydrochlorothiazide (160/12.5 mg)
Hypertension|Diabetes mellitus, Type 2 Phase 4 NCT00239538
US WorldMeds LLC|National Institute on
Drug Abuse (NIDA)
Drug: lofexidine HCl Renally impaired subjects Phase 1 NCT02313103
University of Washington|Paul G. Allen
Family Foundation
Drug: botox; normal saline Painful bladder syndrome|Interstitial cystitis Phase 4 NCT00194610
Children’s Hospital of
Philadelphia|Bayer|University of
Pennsylvania
Drug: paracervical nerve block; sham
paracervical block
Pain Phase 4 NCT02352714
University of Alabama at
Birmingham|National Heart, Lung, and
Blood Institute (NHLBI)
Drug: losartan Anemia, sickle cell|Sickle cell
disease|Kidney disease|Hypertension|
Proteinuria
Phase 2 NCT02373241
University of Alberta|Vancouver Coastal
Health Research Institute
Drug: warfarin Atrial fibrillation|Thrombus due to heart
valve prosthesis|Deep venous
thrombosis|Thromboembolism|DVT
Phase 4 NCT02376803
National Heart, Lung, and Blood Institute
(NHLBI)
Drug: melatonin; methylxanthine|
Procedure: light therapy
Sleep disorders, circadian rhythm NCT00387179
Orphan Medical Drug: sodium oxybate Narcolepsy Phase 3 NCT00049803
National Institute of Mental Health (NIMH) Drug: low-dose sodium oxybate;
high-dose sodium oxybate; low-dose
zolpidem; high-dose zolpidem;
Placebo
Sleep NCT00777829
Massachusetts General Hospital Drug: ramelteon; Placebo Huntington’s disease|Parkinson’s
disease|Dementia with lewy bodies|Sleep
disorders|Circadian dysregulation
NCT00907595
Takeda Drug: ramelteon; Placebo Circadian dysregulation Phase 4 NCT00492011
Massachusetts General Hospital Drug: zolpidem CR; Placebo Dementia|Alzheimer disease|Dementia,
vascular|Sleep disorders|Circadian
dysregulation
NCT00814502
Vanda Pharmaceuticals Drug: tasimelteon; Placebo Non-24-H sleep-wake disorder Phase 3 NCT01163032
Vanda Pharmaceuticals Drug: tasimelteon; Placebo Non-24-H sleep-wake disorder Phase 3 NCT01430754
Cephalon|Teva Pharmaceutical Industries Drug: PROVIGIL 200 mg; armodafinil
250 mg; armodafinil 200 mg;
armodafinil 150 mg; Placebo
Chronic shift work sleep disorder Phase 3 NCT00236080
Child Psychopharmacology Institute Drug: risperidone Sleep disorders, circadian
rhythm|Insomnia|psychomotor agitation
NCT00723580
Cephalon|Teva Pharmaceutical Industries Drug: CEP-10953 (Armodafinil) Narcolepsy|Sleep apnea, Obstructive|Sleep
apnea Syndromes|Shift-work sleep disorder
Phase 3 NCT00078312
Vanda Pharmaceuticals Drug: tasimelteon Smith-Magenis syndrome|Circadian Phase 2 NCT02231008
Vanda Pharmaceuticals Drug: tasimelteon Non-24-H sleep-wake disorder Phase 3 NCT01429116
Takeda Drug: ramelteon; Placebo Sleep disorders, circadian rhythm Phase 2 NCT00593736
(Continued)
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TABLE 1 | Continued
Sponsor/Collaborators Interventions Conditions Phase NCT Number
Boehringer Ingelheim Drug: pharmaton caplets; Placebo Sleep disorders, circadian rhythm Phase 2 NCT02199847
Sheba Medical Center Drug: melatonin Delayed sleep phase syndrome Phase 1 NCT00282061
Cephalon|Teva Pharmaceutical Industries Drug: armodafinil 150 mg/day;
Placebo
Excessive sleepiness|Shift work sleep
disorder
Phase 3 NCT00080288
National Human Genome Research
Institute (NHGRI)|National Institutes of
Health Clinical Center (CC)
Drug: dTR melatonin (NIH CC PDS);
melatonin CR
Device: phototherapy (bright light)
Developmental delay
disorders|Chromosome deletion|Mental
retardation|Sleep disorders, circadian
rhythm|Self injurious behavior
Phase 1 NCT00506259
Brigham and Women’s
Hospital|Sunovion|Massachusetts
General Hospital
Drug: eszopiclone; matching Placebo Shift-work sleep disorder NCT00900159
Vanda Pharmaceuticals Drug: tasimelteon 20mg capsule;
tasimelteon 2mg I.V.
Non-24-H-sleep-wake disorder Phase 4 NCT02130999
Neurim Pharmaceuticals Ltd. Drug: melatonin (circadin); Placebo Non-24 H sleep-wake disorder|blindness Phase 2 NCT00972075
Eunice Kennedy Shriver National Institute
of Child Health and Human Development
(NICHD)|National Institutes of Health
Clinical Center (CC)
Drug: hydrocortisone; Placebo;
hydrocortisone and melatonin;
melatonin
Jet lag syndrome Phase 2 NCT00097474
Teva Pharmaceutical Industries|United
BioSource Corporation
Drug: modafinil/armodafinil Narcolepsy|Obstructive sleep apnea|Shift
work sleep disorder
NCT01792583
Vanda Pharmaceuticals Drug: VEC-162 Circadian rhythm sleep disorders Phase 2 NCT00490945
Vanda Pharmaceuticals Drug: tasimelteon Non 24 H sleep wake disorder Phase 3 NCT01218789
Cephalon|Teva Pharmaceutical Industries Drug: armodafinil 100–250 mg/day Excessive daytime
sleepiness|Narcolepsy|Obstructive sleep
apnea/hypopnea syndrome|Chronic shift
work sleep disorder
Phase 3 NCT00228553
Brigham and Women’s Hospital|National
Center for Complementary and
Integrative Health (NCCIH)
Drug: vitamin B12 Sleep disorders, circadian rhythm NCT00120484
internal clock synchronized to sunrise and sunset (Johnson,
1990).
While light is the predominant stimulus that entrains the
phase of the clock, a variety of other stimuli also affect
entrainment. Of particular relevance in terms of human health
and disease, inputs including food consumption, exercise, and
social interactions can shift clock phase. These non-photic stimuli
generally shift the clock when they occur during the circadian
inactive phase (i.e., during the night in humans) (Rosenwasser
and Dwyer, 2001).
In recent years, the molecular “gears” of the circadian clock
have been elucidated. A series of interlocking negative feedback
loops involving transcription, translation, and post-translational
phosphorylation form the molecular clockwork. At its core, the
transcriptional activators BMAL1, CLOCK and NPAS2 activate
the Period (Per1 and Per2) and Cryptochrome (Cry1 and Cry2)
genes (Mohawk et al., 2012). PER and CRY transcripts and
proteins gradually accumulate during the daytime, associate
with one another and translocate into the nucleus during the
evening, and interact with the CLOCK/NPAS2:BMAL1 complex
to repress their own transcription. The PER and CRY proteins
are progressively phosphorylated by a CK1 kinase during the
night, targeting them for ubiquitylation and eventual degradation
by the proteasome, relieving their transcriptional autorepression
and beginning the cycle again. The timing of this feedback loop
takes about 24 h to complete. Because CK1 phosphorylation of
PER and CRY regulates the timing of degradation of these protein
and the link to a specific human circadian phenotype, CK1 is
a target under investigation for its therapeutic potential. Other
clock components represent potential drug targets, although little
is available in the public domain confirming pharmaceutical
investment in these targets.
A secondary or modulatory protein loop modifies the
core clock loop. REV-ERBα transcription is also activated by
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the BMAL1/CLOCK and repressed by CRY/PER, resulting
in circadian oscillations of REV-ERBα. In turn, REV-ERBα
represses BMAL1 and CLOCK transcription. This REV-
ERBα/RORα feedback loop modulates the core circadian clock
(Bugge et al., 2012). REV-ERBα has also generated interested as a
drug target.
Circadian Rhythms and Disease
Underlying genetic mutations have been discovered which lead
to abnormal circadian rhythms. In this review we refer to these
genetic-driven circadian abnormalities as Primary Circadian
Disorders. For example, some cases of advanced sleep phase
disorder (ASPD) and delayed sleep phase disorder (DSPD),
characterized by a circadian phase that is either “fast” or “slow,”
respectively, are due to mutant forms of key clock proteins.
Familial forms of ASPD arise from mutations in either CK1 delta
or in a phosphorylation site in the PER2 protein targeted by CK1.
Specific CK1 variants are also associated with DSPD, and 75%
of DSPD patients are homozygous for a shorter allele of PER3
that affects phosphorylation by CK1. These human circadian
phenotypes are predicted by the spontaneous mutations in CK1
that result in the circadian period mutants found in hamster,
Tau, and in Drosophila, double-time. In general, it appears that
increasing CK1 activity leads to a shortened circadian period.
Thus, CK1 activity is an important regulator of circadian timing
and a potential target for therapeutic intervention. Clearly, it is
critical to take into account the circadian phenotype and phase
of an individual to predict clinical outcome in trials of drugs
that modulate CK1. As in clinical trials for oncology treatments,
companion diagnostic (CDx) tests that genotype for specific
clock gene mutations would allow selection of the target patient
population. Therefore, as in oncology, these genetic disorders
provide the opportunity to demonstrate, as a proof of principle,
the efficacy of the drug mechanism in a targeted population,
with the goal of expanding therapeutics into Secondary Circadian
Disorders (see below).
In addition tomutations in core clock genes, genetic variations
that affect the timing of the circadian cycle of humans may
also exist. For example, polymorphisms in Clock are associated
with morning vs. evening preference in humans (Katzenberg
et al., 1998). A recent paper describes an association of a Per3
polymorphism with bipolar disorder (Karthikeyan et al., 2014).
Diagnostics that detect these kinds of genetic markers would
provide a mechanism to enrich enrollment in clinical trials with
patients most likely to benefit from specific circadian therapies.
Beyond the genetic disorders discussed above that are the
direct result ofmutations in clock genes or disrupted entrainment
of the circadian system, there is a growing appreciation
that circadian abnormalities may be a key core symptom
of a variety of diseases including metabolic disorders, mood
disorders, and dementia. In this review we refer to circadian
abnormalities that are closely associated with another disease
as Secondary Circadian Disorders. In Secondary Circadian
Disorders, circadian disorganization may present both as a
symptom of the disease, and as a potential risk factor contributing
to disease pathogenesis (Golombek et al., 2013; Smolensky et al.,
2014a,b; Zelinski et al., 2014). An instructive example is the
occurrence of circadian abnormalities in patients with metabolic
disorder. The growing appreciation of the role of clock proteins
in metabolism suggests several potential molecular targets for
therapeutics aimed at treating obesity. A feedback between
the central circadian clock and peripheral oscillators in liver,
skeletal muscle and other tissues helps to coordinate the complex
processes of food intake, activity, and lipid homeostasis (Feng
and Lazar, 2012). Disruption of these highly regulated interacting
rhythms by rotational shift work, for example, is a risk factor for
developing metabolic syndrome, obesity, and diabetes mellitus
(Feng and Lazar, 2012; Bailey et al., 2014; Maury et al., 2014).
While not all obese patients may suffer from circadian disruption,
phenotyping, and appropriately regulating the sleep-wake cycles
of patients in therapeutic trials for obesity may be critical to
uncovering the full potential of a drug. Indeed, individualizing
the timing of drug administrationmay be an unappreciated factor
to improve efficacy, especially in a population where sleep-wake
disruption is overrepresented.
Abnormal circadian rhythms are also common in patients
with mood disorders. Bipolar disorder patients have been
reported to have unstable and lower amplitude circadian rhythms
(McCarthy and Welsh, 2012; Seleem et al., 2014) while those
suffering from major depressive disorder appear to be phase
delayed. It has been shown that circadian programs of gene
expression are distinctly altered in depressive patients (McCarthy
and Welsh, 2012; Karatsoreos, 2014). While the long-standing
hypothesis has been that circadian disruption may be a causal
factor in these disorders, circadian-based treatments have not
always shown pronounced efficacy. There is an ongoing debate
regarding the efficacy of agomelatine, an approved treatment
of major depressive disorder in Europe and Australia although
the drug is not approved for this indication in the US (Gahr,
2014). A recent prospective study suggested that treatment
responsiveness was related to circadian phenotype. Patients with
major depressive disorder that scored as a morning type were
more likely to respond to agomelatine treatment than those that
scored as an evening type (Corruble et al., 2013). Thus, treatment
regimes informed by an individual patient’s circadian phenotype
and/or administered at a specific circadian phase might enhance
the therapeutic benefit for this chronobiotic.
Seasonal affective disorder (SAD) represents a sub-type of
mood disorder closely linked to the circadian system. SAD affects
individuals who become depressed during the short daylight
periods of winter. One leading hypothesis of the cause of SAD
suggests it a results from circadian misalignment (Lewy et al.,
2007), or difficulty entraining due to the absence of bright
light in morning or evening. Therapy with bright light and
melatonin is effective for some SAD patients, and is thought to
act by advancing or delaying phase to re-synchronize the clock.
Especially in this disorder, treatment aligned with the individual
patient’s circadian phase is likely to improve outcomes.
In dementia patients, especially those suffering from AD,
up to 25% experience sundowning, a disturbing syndrome
characterized by agitation, worsening cognitive function, pacing
and wandering in the evening/night, and daytime sleepiness.
A patient’s reduced internal distinction between night and day,
caused by the low amplitude oscillation of their circadian
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clock, appears to contribute to sundowning (Khachiyants et al.,
2011). Therapeutics that enhance the amplitude of the circadian
oscillator could benefit this patient population.
Finally, the recently approved drug, tasimelteon, is prescribed
for patients with Non-24-h sleep-wake disorder (Non-24). Non-
24 is a consequence of the failure of the circadian system to
entrain to the external 24-h day. A majority of Non-24 patients
are blind; and up to 70% of totally blind individuals may suffer
from Non-24. The absence of light perception leads to the lack
of clock entrainment, and as a result the sleep-wake cycle is
free-running. Non-24 is the first circadian disorder for which
a pharmaceutical intervention, tasimelteon, has been approved.
Because Non-24 patients express a range of free-running tau
(from 23.7 to 25.3 h) (Dressman et al., 2012), consideration of
their circadian phenotypes proved to be key to successful clinical
trials (see further discussion of the clinical trial, below).
Considering that circadian rhythmicity is ubiquitous and
closely intertwined with both normal physiological processes
and disease states, any therapeutic approach targeting a disease
(either a “circadian” disorder, or one with rhythmic components)
must take into account the timing of the intervention relative
to the circadian system of the individual. The experience in
drug development for oncology demonstrates the value of
a personalized medicine approach to discovering and testing
therapeutics.
Definition of Personalized Medicine
Personalized medicine can be defined as a targeted prevention
and treatment regimen that is developed for an individual using
data gathered from medical records and diagnostic analysis of
“biomarkers,” or specific biological markers that distinguish one
individual from another. Most often, biomarkers are genetic;
however, biomarkers can also be phenotypic, such as circadian
subtypes (e.g., advance phase or delayed phase syndrome).
Ultimately, the goal of personalized medicine is to give the right
patient the right treatment at the right time.
Following the completion of the Human Genome Project over
10 years ago, the cost and time for genomic sequencing has
decreased exponentially. On average, sequencing of a human
genome decreased from $1 billion in 2003 to between $3–
5000 today (Personalized Medicine Coalition, 2014), with a
time to result from ∼7 years decreased to ∼2 days. In
addition to influencing all of biological research, mapping of
the genome has also translated to clinical chemistry, with many
therapeutics now designed to target specific proteins, protein
classes, or even mutated forms of a protein. In contrast to
traditional chemotherapies, which function against any actively
dividing cells, targeted therapeutics act on a molecule in the
signaling pathway driving a specific tumor (http://www.cancer.
gov/cancertopics/factsheet/Therapy/targeted).
The following section will examine the growing field of
personalized medicine in oncology, which has focused on
targeting the genetic abnormalities driving cancer with targeted
therapies. As patients with circadian disorders continue to be
profiled both at the phenotypic and molecular levels, the ability
to subtype patient populations in order to identify the predicted
responsive cohort is critical in ensuring more efficient and more
successful circadian clinical trials.
Personalized Medicine in Oncology
The oncology field has led to the use of personalized medicine
in healthcare, mainly due to the effectiveness of targeted
therapeutics specifically developed to inhibit oncogenic driver
proteins. Currently, targeted therapeutics are available for
patients with melanoma, chronic myeloid leukemia, colon,
breast, and lung cancer. In non-small cell lung cancer (NSCLC),
mutations in two oncogenic driver genes, EGFR and ALK,
make up ∼25–40% of all NSCLC cases (Kwak et al., 2010;
Melosky, 2014). Two FDA-approved EGFR inhibitors and
two FDA-approved ALK inhibitors are commercially available
(EGFR: Gilotrif™, Boehringer Ingelheim and Tarceva R©, Roche;
ALK: Xalkori R©, Pfizer and Zykadia™, Novartis). Each of these
inhibitors requires testing of patients with a unique FDA-
approved diagnostic test (aka CDx) prior to prescription. CDx
assays are FDA regulated as Class III Medical Devices (Olsen and
Jorgensen, 2014) that were demonstrated during the pivotal trial
to show clinical utility in selecting for the responding patient
population, were contemporaneously FDA-approved alongside
the corresponding therapeutic, and are specified in the drug
labeling to be required for use in identifying the target patient
population. Therefore, a CDx is the mechanism to identify the
right patient for the right drug.
Personalized Medicine Growing Pains
Use of CDx in the oncology space was initially met with
resistance; the thought of narrowing the market to a select
patient population does not inherently make financial sense.
However, as drugs in development functioned through a more
selective mechanism of action, it was clear that identification
of responders carrying the genetic target was paramount, as
dictated by the FDA. For example, the small molecule Iressa™
(gefitinib, AstraZeneca) was initially approved in Japan in July
2002 and in May 2003 through the FDA Accelerated Approval
path for NSCLC. Under the Accelerated Approval guidelines,
approved therapeutics are required to complete a post-approval
Phase III study. Completion of the obligatory Phase III Iressa
Survival Evaluation in Lung Cancer (ISEL) trial in 2004 revealed
no improvement in overall survival in patients taking Iressa
vs. placebo (Thatcher et al., 2005). However, an academic
study published that same year suggested that the subset of
Iressa responders correlated to mutations in the tyrosine kinase
Epidermal Growth Factor Receptor (EGFR) gene. Retrospective
analysis of the ISEL data with genetic testing for mutations in
EGFR clearly indicated that patients with mutations in EGFR
responded significantly better to Iressa than patients without
EGFR mutations; interestingly, the patient cohorts carrying the
EGFR mutations were predominantly Asian women with no
smoking history (Lynch et al., 2004). In 2005 FDA responded
to the Iressa-EGFR findings by allowing for use of Iressa only
in patients currently taking the drug and showing a response
or via new clinical trials. The increased control required over
distribution of the drug resulted in a near-complete drop in
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revenue generated in the US. With a much more limited patient
population [EGFR mutations contribute to roughly 20% of
NSCLC (Agarwal, 2012)], AstraZeneca forged ahead to change
their commercialization strategy in countries outside the US.
Interestingly, despite the clear link between EGFR mutation
status and response, restrictions for use were not altered in Japan
and Iressa was approved for use in China, mostly likely based
on its efficacy in Asian populations. To expand to approval
in Western countries, AstraZeneca positioned Iressa as both a
second-line therapy to Taxotere (docetaxel) and partnered with
the diagnostics company, DxS (which was subsequently bought
by QIAGEN), to develop a molecular based assay for genotyping
of EGFR. In 2009, Iressa was approved by the European Union
with the CDx therascreen EGFR RGQ RT-PCR Kit. As of 2011,
Iressa sales in Europe were ∼$150 million, with a total of ∼$520
million globally (Agarwal, 2012).
The “sea change” toward the utilization of CDx for FDA
submission that resulted from the Iressa story, and others not
discussed in this review, was ultimately driven by risk mitigation
- mainly mitigation of the possibility of FDA rejecting approval
of a therapeutic due to the lack of use of a CDx. FDA took
a formal stance on CDx with the release of a draft guidance
in 2011, which was subsequently finalized in August 2014
(http://www.fda.gov/downloads/MedicalDevices/DeviceRegulati
onandGuidance/GuidanceDocuments/UCM262327.pdf). This
guidance defines an In Vitro CDx (IVD), indicates that in
most instances a drug and the CDx should be FDA approved
contemporaneously, outlines the FDA’s regulatory enforcement
policy and regulatory approval pathways for CDx, and discusses
the implementation of labeling requirements upon co-approval
of a drug and IVD assay. It goes without saying that the
FDA oversight is not uniquely positioned to regulate only
oncology therapeutics. Therefore, as part of each and every drug
development program, from oncology to CNS, there could be
questions about whether the drug can be shown to be safe and
effective without enrichment of a particular patient population.
Study Outcomes as a Result of Personalized
Medicine Approaches
There are significant financial benefits to utilizing a CDx strategy
throughout drug development. Following the discovery of ALK-
driven NSCLC in ∼5–10% of the patient population (Soda
et al., 2007), Pfizer proceeded with utilizing a fluorescence in
situ hybridization (FISH) assay to detect the ALK chromosomal
translocation as an eligibility requirement for patient enrollment.
What would have taken years, hundreds millions of dollars, and
thousands of patients to complete, took less than 3 years and
less than 350 patients to achieve statistical power for regulatory
submission and approval (Kwak et al., 2010). The short timeline
and small patient enrollment is not unique to the ALK story. As
shown in Table 2 multiple therapeutics have rapidly progressed
from Phase I to market in less than 5 years through the use of
patient enrichment with CDx.
Although there are less than 20 FDA Approved (Pre-Market
Approval) CDx on the market to date (http://www.fda.gov/Med
icalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/
ucm301431.htm), there are over 100 drugs with
TABLE 2 | Examples of rapidly-progressing therapeutics.
Company Therapeutic Phase I Approval
Roche/Genentech Vemurafenib
(Zelboraf™)
November 2006 August 2011
Pfizer Crizotinib (Xalkori®) December 2007 August 2011
GSK Trametinib (Mekinist™) May 2008 May 2013
Roche/Genentech Ado-trastuzumab
emtansine (Kadcyla®)
June 2009 February 2013
GSK Dabrafenib (Tafinlar®) April 2009 May 2013
pharmacogenomics information within the label (Personalized
Medicine Coalition, 2014) and a projected 30% of drugs in late
clinical development rely on biomarkers for patient enrollment
(http://www.personalizedmedicinecoalition.org/Userfiles/PMC-
Corporate/file/pmc_personalized_medicine_by_the_numbers.p
df). One group has examined the effectiveness of utilizing a
CDx during 676 clinical trials with 199 compounds. Utilizing a
biomarker-driven approach to Phase III trials, the success rate
increased from 28% (no biomarker) to 62% (Falconi et al., 2014;
Olsen and Jorgensen, 2014). Therefore, utilizing a biomarker-
driven clinical trial increased the success rate of Phase III trials,
and subsequent approval, almost 2.5-fold.
Reimbursement Pressure
As discussed earlier, initially the narrowing of oncology patient
populations appeared to translate to a loss in revenue potential
for the therapeutic. However, with the evolution of regulatory
agencies requiring patient enrichment to show safety and
efficacy, and the increasing amount of data supporting faster
and more successful routes to drug approval using CDx, the
thinking has changed from assays being “burdensome” to
assays being “useful” toward successful drug development. In
addition, pressure is increasingly being put on pharmaceutical
companies by insurance providers. Generally, targeted therapies
are significantly more costly to a patient than generalized
therapies; one report approximates the average cost per month
for a branded oncology drug has doubled in the U.S. from $5000
to $10,000 in the past decade (http://www.imshealth.com/deploy
edfiles/imshealth/Global/Content/Corporate/IMS%20Health%2
0Institute/Reports/Secure/IMSH_Oncology_Trend_Report.pdf).
In order to justify reimbursement of such expensive targeted
therapies, insurance companies are requiring diagnostic tests be
performed prior to prescription of a therapeutic. In European
countries, a high level of scrutiny has been placed on newly
developed therapeutics in comparison to existing treatments.
For example, the UK National Institute for Health and Care
Excellence (NICE) does not recommend the ALK inhibitor,
Xalkori R© for use in ALK-driven NSCLC, based on the ruling
that the drug does not offer value for money.
In order to align with the fast-paced personalized medicine
trend in healthcare and to ensure that each patient receives
the most appropriate treatment for their disease, payers
should support the use of CDx. Promotion of standardization
of coverage and value-based reimbursements; reimbursement
strategies that cover research-based innovations, such as Next
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Generation Sequencing; and flexibility in medical coding and
billing facilitate the use of personalized medicine approaches to
ensure the right patient receives the right treatment at the right
time.
Personalizing Therapeutic Approaches for
Circadian Disorders
As discussed above, several genetic mutations have been
identified that lead to a primary circadian disorder. Many more
diseases have concomitant circadian abnormalities, which we
refer to as secondary circadian disorders. For both types of
disorders, phenotyping of the circadian disruption prior to
initiation of therapy is critical to success—timing is everything
when it comes to treatment of circadian dysfunction. In fact,
measuring multiple rhythms within an individual is essential,
as some disorders result from a misalignment of endogenous
rhythms (Lewy et al., 2007). Traditional methods for monitoring
the circadian phase and period in ambulatory humans include
activity and body position monitoring via wearable devices
(Bonmati-Carrion et al., 2015) and body temperature via wrist
skin temperature (Kolodyazhniy et al., 2012). In a laboratory
setting, multiple blood or saliva sampling to assess melatonin or
other hormone patterns has been employed (Keijzer et al., 2014).
In addition, the recent description of the rhythmic expression
pattern of nearly half of the genome (Zhang et al., 2014)
provides the opportunity to develop more and potentially better
biomarkers for assessing the phase and period of individuals.
Finally, mobile smartphones provide a unique and potentially
highly effective method to collect robust data on circadian
rhythms from an individual (Roenneberg, 2013). Thus, collecting
robust data on a patient’s circadian phenotype is both technically
feasible and critical to the successful treatment of a circadian
abnormality.
Tasimelteon, a Circadian Success Story
Approved on January 31st, 2014, HETLIOZ R© (tasimelteon) is the
first FDA approved treatment for adults with Non-24-H Sleep-
Wake Disorder (Non-24), which is a rare circadian disorder
occurring mostly in the totally blind. Vanda reports HETLIOZ R©
U.S. sales grew to $5.2 million in the first full quarter after launch.
However, the road to approval was winding, with several failed
clinical trials in other indications before the drug successfully
demonstrated efficacy in Non-24.
Tasimelteon is a melatonin receptor MT1/2 agonist that
was originally discovered by BMS (previously known as BMS-
214,778) and licensed to Vanda Pharmaceuticals. Vanda opened
an IND in 2004 for Shift Work Disorder, Jet Lag Disorder (due
to eastward travel) and DSPD, however to date Vanda has not
sought approval for any of these indications. Following on the
success of another melatonin agonist, ramelteon (Rozerem R©),
which is approved in the US for treatment of insomnia,
tasimelteon was tested in clinical trials for sleep disorders,
including a Phase II trial on circadian rhythm sleep disorders
and several phase III primary insomnia trials. However, the
drug failed to show significant efficacy in these clinical trials.
Additionally, the drug was also considered as a treatment for
depression.
After several years of frustratingly weak results in other
indications, Vanda demonstrated that tasimelteon produced
phase shifts in healthy adults (Neubauer, 2015). Vanda then
began Phase III clinical trials of the drug in a population with
Non-24. There are ∼1,300,000 blind people in the United States
and∼10% of these individuals have no light perception. Without
light input these totally blind individuals free run, drifting in
and out of phase with the environment, impairing their ability
to work, disrupting family life and impacting their overall health.
Tasimelteon treatment entrained a higher number of totally blind
to a 24-h cycle vs. placebo and the drug was approved in the
US and available to appropriate patients via specialty pharmacy
(Neubauer, 2015).
Vanda faced several significant challenges in the clinical trials
testing the efficacy of tasimelteon for Non-24. The first task
was setting the appropriate enrollment criteria and developing a
screening protocol to capture the desired subjects. The number
of enrollment failures in the SET trial was high; 391 subjects
were screened; yet only 84 were enrolled in the randomized trial
(Lockley et al., 2013). Vanda did not study subjects with a tau
shorter than 24 h even though it is reasonable to expect that
subjects with a short tau would eventually respond to treatment
once the timing of dosing coincided with a sensitive phase in
the circadian rhythm. Subjects with tau shorter than 24 h were
excluded from the study because the dosing regime was fixed to
administer the drug at 1 h prior to bedtime, based on concerns
about drug-induced somnolence. Even though Vanda has not
done a PRC for the drug, they were concerned that they would
be unable to show efficacy in patients with a short tau if the drug
was always to be taken at 1 h prior to bedtime.
Timing of treatment was not always aligned to the sensitive
circadian phase of the treated subject’s rhythm. The drug was
always taken at 1 h prior to bedtime and althoughVanda had tried
to initiate dosing when subjects were in phase, 16% of subjects
were out of phase when dosing was started. Subjects that were out
of phase at the start of trial took a longer time on treatment to see
efficacy, which contributed to the length of trial (Lockley et al.,
2013). Circadian tau at was measured at 1 month and 7 months
of treatment in the RESET trial (Lockley et al., 2013). RESET took
almost 2 years to complete.
A final challenge in the tasimelteon trial was the use of
entrainment as an outcome measure; an endpoint that is more
correctly considered a proof of mechanism for the drug, not
a proof that the drug is a treatment for the disorder. Only
clinical benefit, defined by an improvement in how patients feel,
function or survive, constitutes an acceptable primary endpoint
for registration of a drug. An improvement in sleep did constitute
a positive clinical outcome. The tasimelteon-treated group had
significant improvement in the duration and timing of nighttime
sleep and a significant decrease in daytime napping. Thus,
tasimelteon is now available to provide treatment for blind
patients suffering from Non-24.
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Final Perspective
Circadian biologists have been collecting human subject
circadian data in the research setting for decades, but few
circadian drug treatment trials have been attempted. The
general population has a growing familiarity with circadian
biology in general and with their own unique rhythms,
thanks to smart phone apps and wearable personal activity
trackers. Nevertheless, drug developers have not yet linked
the profound impact of circadian dysfunction on health to an
influx of circadian drugs into pharma pipelines. The growing
awareness of the link between disrupted circadian rhythms
and obesity necessitates developing clinical trial strategies to
effectively demonstrate the therapeutic benefit of drugs that
alter circadian rhythms (chronotherapies). Better education of
clinical researchers in the science of circadian biology is essential
to developing enrollment criteria that will effectively capture
the appropriate patient population. It should be apparent that
circadian therapies must also be appropriately timed; treatment
must be adjusted to be consistent with the patient’s circadian
phenotype, requiring a high degree of physician expertise
and skill in interpreting circadian rhythms and possibly even
daily input on scheduling dosing. Technological advances in
remote data collection and the growing acceptance of sharing
personal data will aid in personalizing circadian therapies
to the appropriate patient. As data collection is improved,
it may become obvious that not all patients will benefit
from a specific therapy, as occurred in oncology. Biomarker
strategies must be incorporated early in development to reduce
screening failures and improve the potential to see efficacy,
thus reducing the number of failed clinical trials. Biomarkers
in this sense do not have to be genetic markers, but could
be a clear circadian phenotype based on activity or other
rhythm data.
Finally, circadian biologists have a deep appreciation of the
negative impact on overall health of misaligned and disrupted
rhythms, but simply demonstrating correction of the rhythm will
not be sufficient for approval of a drug. Circadian drugs must also
demonstrate that clinically relevant endpoints are improved by
circadian adjustments.
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